Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03BBU
|
|||
| Former ID |
DNCL002419
|
|||
| Drug Name |
Lucatumumab
|
|||
| Synonyms |
HDC122
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 2 | [1] | |
| Company |
Novartis Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00231166) Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma. U.S. National Institutes of Health. | |||
| REF 2 | Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.Leuk Lymphoma.2012 Nov;53(11):2136-42. | |||
| REF 3 | Agonistic CD40 antibodies and cancer therapy | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.